Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oncologists Move Against Medicare Part B Drug Payment, Pricing ‘Attacks’

Executive Summary

Remember what happened the last time physician groups opposed federal efforts to curtail Medicare spending on Part B drugs?

You may also be interested in...



Medicare Part B, Breakthrough Drugs Get Reimbursement Boost In Senate COVID-19 Bill

Legislation allows sponsors to request HCPCS code even before US FDA approval, but would extend the sequester until 2030 to pay for the temporary increase in payments for Part B drugs.

Part B Drug Competitive Bidding Program Revival: Vendor Request Coming Soon

Distributors, specialty pharmacies and PBMs are in a better position now to act as vendors then they were a decade ago, when Medicare unsuccessfully tried to implement a Medicare Part B prescription drug competitive acquisition program, HHS Secretary Azar points out.

Part B Drugs Could Be Switched To Part D Under Trump Pricing Plan

Bringing the hammer down on biopharma, HHS Secretary Azar says department could use demonstration projects to switch drugs from Medicare Part B to Part D.

Related Content

Topics

UsernamePublicRestriction

Register

ID1132090

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel